INTRODUCTION {#sec1-1}
============

Propofol is the preferred induction agent for Laryngeal mask airway (LMA) insertion which is widely used for providing general anesthesia in children. Propofol is a nonopioid, nonbarbiturate, sedative-hypnotic agent with rapid induction and recovery times and antiemetic effects.\[[@ref1]\] It allows easy insertion of LMA by depressing airway reflexes. However, adverse effects include dose-dependent cardiorespiratory depression, injection pain, and having no analgesic properties.\[[@ref2][@ref3]\] Ketamine causes little or no cardio-respiratory depression and unlike propofol, has pain relieving properties. Ketamine use as a single induction agent, however, is limited by emergence hallucinations, elevation of blood pressure and heart rate due to its sympathomimetic effects, and increased intracranial pressure.\[[@ref4][@ref5]\] Effectiveness of the two agents -- propofol and ketamine -- in combination (ketofol) has been recently demonstrated and may provide a novel induction agent with favorable hemodynamics and reduced side effects attributed to either drugs.\[[@ref6]\] To date, ketofol has been used most extensively for procedural sedation in the Emergency Department with encouraging results,\[[@ref3][@ref7]\] but has not yet been standardized as an induction agent. Bispectral index (BIS) monitoring has emerged as a convenient and versatile tool to titrate hypnotic agents and to reduce drug consumption. BIS is a dimensionless number scaled from 100 to 0, with 100 representing an awake electroencephalogram and 0 representing electrical silence.\[[@ref8]\] This study was designed to investigate ketofol as a suitable induction agent alternative to propofol for insertion of LMA in children considering insertion conditions, hemodynamic stability, local pain at injection site, and recovery score.

MATERIALS AND METHODS {#sec1-2}
=====================

After obtaining institutional ethics committee approval and informed parental consent, 100 children of ASA class I and II, of both sex, age ranging from 3 to 15 years and undergoing elective short surgical procedures under general anesthesia were included in the study. Children who were at risk of regurgitation, with known allergy to either agents, or with difficult airway were excluded. Children were randomly assigned to one of two groups 50 patients each; *P* group (propofol), KP group (ketofol). Randomization was by the envelope method and the investigator and observer were blinded. Upon arrival at the operating room, patients were preoxygenation with 100% oxygen for 3 minutes during which the standard monitors; electrocardiogram, noninvasive blood pressure and pulse oximetry were attached to the patient. BIS monitor electrodes (Aspect Medical System, Vista™, MA, USA) were applied on the skin of left side of the forehead after cleansing with alcohol. One minute before induction, baseline readings were recorded. Providers were given one 20 ml syringe and one 10 ml syringe for rescue if needed. The clinician and observer were blinded to the medication and doses being administered during induction. The 20 ml syringe in both groups looked identical (appeared to be propofol only) but depending on the group they were randomized to, it represented either 2 mg/kg of propofol (P group) or 0.75 mg/kg of ketamine and 1.5 mg/kg of propofol (KP group). Normal saline was added to the syringes up to 20 ml for blinding purposes. The 10 ml rescue syringe, if used, (due to any patient responding to stimulus after induction) represented 1 mg/kg of propofol (P group) or 0.25 mg/kg of ketamine and 0.5 mg/kg of propofol (KP group). In all patients general anesthesia was induced using a syringe perfuser at a constant rate 250 ml/h and the response was titrated until the target level of BIS 40 was obtained. As soon as BIS was decreased to index values of 40, an appropriate size LMA was inserted by an experienced anesthetist who was unaware of which group the child was in. A maximum of three attempts were allowed for the insertion of the LMA and Assessments were done only for the first attempt. Following insertion of the LMA, the cuff was inflated with air until effective ventilation was established or the maximum recommended inflation volume was used. Patients were kept on spontaneous respiration and anesthesia was maintained with sevoflurane 1-2%.

Assessments {#sec2-1}
-----------

The times needed for loss of verbal contact and for loss of eyelash reflex were recorded. Injection pain and the conditions for LMA insertion were assessed by the same anesthetist. Pain on injection was graded using a four-point scale by Cameron *et al*.\[[@ref9]\]; 0: no pain, 1: mild pain (grimace), 2: moderate pain (grimace + cry), 3: severe pain (cry + withdrawal). The conditions for LMA insertion were scored according to mouth opening (1: full, 2: partial, 3:nil), gagging or coughing (1: nil, 2: slight, 3: gross), swallowing (1: nil, 2: slight, 3: gross), laryngospasm (1: nil, 2: partial, 3: complete), head or limb movements (1: nil, 2: slight, 3: gross), ease of LMA insertion (1: easy, 2: difficult, 3: impossible).\[[@ref10]\] Jaw relaxation was assessed according to Young\'s criteria\[[@ref11]\]; (excellent: absolutely relaxed with no muscle tone, satisfactory: moderately relaxed with some muscle tone, poor: poorly relaxed with full muscle tone).

The overall LMA insertion conditions were graded as excellent, satisfactory, and poor\[[@ref12]\] as follows:

Excellent: No adverse response, i.e., no gagging or coughing, no patient movement or laryngospasm.Satisfactory: Adverse response to airway manipulations, but not affecting the insertion of LMA.Poor: a. Moderate to severe adverse responses requiring additional boluses of drugs,b. More than two attempts were required for LMA insertion.

Mean arterial pressure (MAP), heart rate (HR), SpO~2~ were recorded before induction of anesthesia (t~0~), immediately following induction of anesthesia (t~1~), immediately after LMA placement (t~2~), 3 and 5 minutes after LMA placement (t~3~, t~4~). Complications such as bradycardia, muscle rigidity, and excessive secretions, were recorded. Incidence of apnea (absence of spontaneous respiration for \> 20 seconds) was noted. At the end of surgery and after LMA removal, incidence of postoperative nausea and vomiting was recorded. Recovery was evaluated using the Aldrete score (1-10 range) ([Appendix](#App1){ref-type="table"}).\[[@ref13]\]

###### 

Aldrete\'s postanesthesia recovery scoring system\[[@ref13]\]
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Statistical analysis {#sec2-2}
--------------------

A sample size of 37 patients per group was needed to detect an intergroup difference of at least 20% (α =0.01, two-sided, power = 90%) with two-sample *t*-test. All values were expressed as mean ± SD, median (range) or number (percent) unless otherwise stated. All statistical analyzes were performed using SPSS for Windows 13.0. (SPSS Inc., Chicago, IL, USA). The categorical data were compared using a Chi-square test. Parametric data were compared using one-way analysis of variance (ANOVA) and within-group comparisons at different time intervals were assessed using a paired *t*-test. A value of *P* \< 0.05 was considered statistically significant.

RESULTS {#sec1-3}
=======

Demographic data were similar between the two groups regarding patients' weight, age, gender, height, and duration of surgery \[[Table 1](#T1){ref-type="table"}\]. Verbal contact and eye lash reflex were lost earlier in patients in the KP group (33.5 ± 2.10 and 35.6 ± 1.9 seconds respectively) than patients in the *P* group (38.0 ± 2.8 and 41.6 ± 2.2 seconds respectively) (*P* \< 0.05) \[[Figure 1](#F1){ref-type="fig"}\]. The incidence of injection pain was significantly lower in the ketofol KP group (10%) than in the propofol *P* group (80%) (*P* \< 0.001). The distribution of pain scores is shown in [Table 2](#T2){ref-type="table"}. Induction time (time to reach BIS of 40) was shorter in the ketofol group (150 ± 23.5 seconds) than in the propofol group (205 ± 37.4 seconds) (*P* \< 0.005) \[[Figure 2](#F2){ref-type="fig"}\]. The median summed score describing the overall LMA insertion conditions was significantly better in the KP group \[6.4 (6-7)\] compared with *P* group \[7.5 (6-9)\] (*P* = 0.023) \[[Table 3](#T3){ref-type="table"}\]. The incidence of excellent (absolute) jaw relaxation and full mouth opening was higher in the KP group 45 patients (90%) than in the *P* group 38 patients (76%) (*P* \< 0.005). Excellent LMA insertion conditions were observed in 45 patients (90%) in the KP group and 38 patients (76%) in the *P* group. Poor insertion conditions were observed in one patient (2%) in the KP group and 6 patients (12%) in the *P* group \[[Table 3](#T3){ref-type="table"}\]. The mean blood pressure was significantly decreased in the *P* group compared to the KP group at all measurement points (*P* \< 0.05) and was significantly lower than the basal level (t~0~) at t~1~, t~2~, t~3~, t~4~ in the *P* group (*P* \< 0.005) \[[Table 4](#T4){ref-type="table"}\]. The heart rate was significantly decreased in the *P* group (*P* \< 0.05), while it remained comparable to basal level in the KP group at all measurement points \[[Table 5](#T5){ref-type="table"}\]. The difference between the two groups was found to be statistically significant (*P* \< 0.005). The incidence of apnea was higher in the *P* group than in the KP group, 17 patients (34%) vs. 3 patients (6%) respectively (*P* \< 0.05). The mean duration of apnea was higher in the *P* group than in the KP group (47.65 ± 11.20 seconds vs. 30.50 ± 3.10 seconds respectively) (*P* \< 0.05). There was no significant difference in the recovery score between the *P* group and KP group \[[Table 6](#T6){ref-type="table"}\].

###### 

Demographic data of patients. Values are mean± (SD) or number (proportion)
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![Verbal contact and eye lash reflex loss times, propofol vs. ketofol](AER-7-194-g003){#F1}

###### 

Incidence of injection pain (values are number) -propofol vs. ketofol
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![Time to reach BIS to 40 (induction time), propofol vs. ketofol](AER-7-194-g005){#F2}

###### 

LMA insertion conditions (number) or median (range) -propofol vs. ketofol
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###### 

Changes in mean blood pressure (MAP) in mm Hg (mean±SD) -propofol vs. ketofol
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###### 

Changes in heart rate (HR) (beats/min) (mean±SD) -propofol vs. ketofol
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###### 

Untoward effects and recovery (mean±SD) or n (%)- propofol vs. ketofol
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DISCUSSION {#sec1-4}
==========

Smooth and successful insertion of LMA necessitates the adequate depth of anesthesia to suppress pharyngeal and laryngeal reflexes and prevent airway complications. Currently, propofol is the most widely used induction agent for LMA insertion as it provides rapid induction and excellent jaw relaxation, but it has many disadvantages such as pain at injection site, involuntary limb movement, prolonged apnea, and hypotension. Dose of propofol required to produce adequate conditions for LMA insertion is suggested to be more than 3 mg/kg in children.\[[@ref14]\] When a high dose of propofol is used, it causes cardiorespiratory depression.\[[@ref15]\] In an attempt to reduce propofol adverse cardiorespiratory depressant effects, the combined use of propofol and ketamine (ketofol) has been proposed with great success but little is known in the literature about the use of ketofol as an induction agent compared to propofol.\[[@ref16][@ref17]\]

The main finding of this study was that ketofol as an induction agent has rapid onset of action, lower incidence of injection pain, and better overall conditions and ease of LMA insertion. It provided better hemodynamic stability and lower incidence of adverse effects when compared to propofol.

In this study, the onset of clinical hypnosis, proved by the times needed for loss of verbal contact and eye lash reflex, was earlier in the ketofol group compared to the propofol group (*P* \< 0.05). Consistent with our results, Frey and colleagues\[[@ref18]\] stated that ketofol was associated with shorter time until sedation compared to propofol. Induction time (time to reach BIS of 40) was faster in the ketofol group (150 ± 23.5 seconds) than in the propofol group (205 ± 37.4 seconds). In contrast to our results, Sakai *et al*.\[[@ref19]\] found an additive effect of propofol and ketamine for achieving the hypnotic endpoints; however, the mixture did not depress the BIS values in proportion to its hypnotic effect and they attributed this to the small concentrations of propofol used and/or ineffectiveness of ketamine on BIS. This contrast between this study and that of Sakai can be explained by different methodologies, different concentrations of the ingredients within the admixture, and different infusion time and rate.

The high incidence of pain on injection is an annoying problem during the use of propofol. Adding lidocaine to propofol to reduce this problem is a common practice but despite this the incidence of pain remains unacceptably high (20-30%).\[[@ref20]\] Pain with propofol injection is attributed to the free aqueous concentration of propofol in the emulsion\[[@ref21]\] or to the activation of kininogens.\[[@ref22]\] In our study, the use of ketofol was found to significantly reduce incidence of pain on injection (10%), compared with propofol (80%) and these results were comparable with previous studies where pretreatment with intravenous ketamine provided a simple and safe method of reducing the incidence of pain on injection of propofol.\[[@ref23][@ref24][@ref25][@ref26]\] Ketamine may activate NMDA receptors either in the vascular endothelium or in the central nervous system. It seems likely that ketamine reduces the propofol injection pain by virtue of its local anesthetic property.\[[@ref23][@ref27]\]

In the present study, the incidence of absolute jaw relaxation and excellent LMA insertion conditions was higher in the ketofol group (90%) than in the propofol group (76%). In agreement with our results, Bahk *et al*. had compared various doses of propofol and ketamine with lidocaine spray for LMA insertion.\[[@ref28]\] They found that ketamine with lidocaine spray may be better than propofol for LMA insertion. Also Begec *et al*.\[[@ref29]\] concluded that the combination of ketamine and propofol may be preferred for LMA insertion in children.

In our study, ketofol showed more hemodynamic stability compared to propofol for LMA insertion in children. When administered with propofol for induction of anesthesia, even in subanesthetic doses, ketamine may produce hemodynamic stability.\[[@ref30][@ref31][@ref32]\] Ketamine 0.5 mg/kg administered before propofol 1.5 mg/kg for LMA insertion preserved hemodynamic stability compared with propofol alone in children\[[@ref33]\] and in adult patients.\[[@ref34]\] Akin *et al*.\[[@ref35]\[ found hemodynamic stability of ketofol in children undergoing cardiac catheterization. Arora *et al*.\[[@ref36]\] proved hemodynamic stability of ketofol in a 1:1 ratio for procedural sedation in adults. Ketofol was associated with improved hemodynamic stability during the first 10 minutes after induction compared with propofol and the authors concluded that ketofol has the potential to be used as an alternative agent for emergency induction during which stable hemodynamics are desirable.\[[@ref37]\] The incidence and mean duration of apnea in the present study were higher in the propofol group than in the ketofol group. Consistent with our results, previous studies\[[@ref16][@ref18][@ref33]\] concluded that the addition of ketamine to propofol is associated with less prolonged apnea and less risk of respiratory depression compared with propofol alone. Also low-dose ketamine added to propofol sedation attenuated propofol-induced hypoventilation and preserved response to carbon dioxide.\[[@ref38]\] Complications as nausea and vomiting, increases in secretions, and emergence hallucinations were not seen in this study. Propofol was effective in eliminating side effects of a subanesthetic dose of ketamine.\[[@ref39]\]

CONCLUSION {#sec1-5}
==========

Ketofol is a safe and effective alternative induction agent for LMA insertion in children with rapid onset of action and lower incidence of injection pain. It provided better LMA insertion conditions, improved hemodynamic stability with less prolonged apnea when compared to propofol.
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